Over the past six months, the company, which is one of the world’s largest purveyors of generic medicines, raised prices more than 20 percent on two dozen products. And Mylan also boosted prices by more that 100 percent on seven other products, according to Wells Fargo analyst David Maris, who called some of the price hikes “exceptionally large.”Mylan's spokestroll basically said "hey, we're not jacking up all of the prices." Which is like a bank robber saying that he didn't take all of the money.
For instance, he cited a 542 percent increase for ursodiol, a generic medicine used to treat gallstones. There was also a 444 percent increase for metoclopramide, a generic drug that treats gastroesophageal reflux disease; and a 400 percent boost in the price for dicyclomine, which combats irritable bowel syndrome. Mylan also raised the price of its tolterodine overactive bladder drug, one of its biggest products in the United States, by 56 percent.